CARB-X FUNDS DEBIOPHARM
CARB-X is awarding Debiopharm International SA of Lausanne, Switzerland, up to $2.1 million in non-dilutive funding with the possibility of $1.6 million more if certain project milestones are met, to advance the development of a new class of antibiotics that inhibit bacterial fatty acid biosynthesis, an essential pathway in many drug-resistant bacterial species. This new class of antibiotics is in development for the treatment of hospital-acquired pneumonia caused by the multidrug-resistant superbug Acinetobacter baumannii.
Emerging Antimicrobials and Diagnostics in AMR 2019
International Matchmaking Symposium on 19-20 November, 2019 in Amsterdam, The Netherlands.